Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lyfgenia
Pharma
With 64 centers activated, bluebird is ready to grow Lyfgenia
Bluebird has started its first patient on its sickle cell disease gene therapy Lyfgenia. And with 64 treatment centers active, there's room to grow.
Kevin Dunleavy
May 9, 2024 1:40pm
Bluebird discusses Lyfgenia launch details and accounting errors
Mar 26, 2024 10:49am
Bluebird secures $175M loan from Hercules Capital
Mar 18, 2024 11:49am
Michigan Medicaid signs deal with bluebird for SCD gene therapy
Mar 11, 2024 11:00am
FDA approves Vertex, CRISPR's Casgevy for beta thalassemia
Jan 16, 2024 3:40pm
JPM24: Bluebird CEO defends Lyfgenia pricing premium, EU retreat
Jan 10, 2024 7:10pm